ENTX Company Profile and Key Details

ENTX has shown mixed momentum, losing 0.0% over the past week and -33.19% over the past quarter, though year-to-date performance is down -19.07%. Short-term trend indicators are bullishly aligned (SMA20 5.48%, SMA50 -11.05%, SMA200 -24.71%). The stock’s 14-day RSI is 50.33 (neutral), while the ATR of 0.18 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -52.8% below its high and over 52.0% above its low. Average 10-day trading volume of 316.65 thousand shares is significantly above the 3-month average of 192.69 thousand, indicating heightened recent market interest.

Entera Bio Ltd. has 45.66 million shares outstanding. The public float is 28.77 million shares, elevated short interest at 0.14% of float. This equals 55.48 thousand shares. The short ratio is 0.23 days. Institutional investors hold 29.54% of the float. Insiders own 24.31%. Schwartz Phillip holds 607.41 thousand shares, Toledano Miranda Jayne has 426.58 thousand shares and Ellis Sean has 178.10 thousand shares. Over the past six months, insider transactions show net buying. They sold 0.00 shares across 0 transactions.

Entera Bio Ltd. generated EPS of -$0.24 over the past year. Five-year average earnings growth is 22.19%. The latest quarter delivered EPS of -$0.07. The next quarter is forecast at -$0.09. Next year's EPS is expected at -$134.38. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 2 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $10.00 to $10.00. The high target offers 557.89% upside. The low target suggests 557.89% downside. The mean target is $10.00. This offers 557.89% upside. Entera Bio Ltd. earnings surprise history is frequent misses against expectations. The quarter that ended November 14, 2025, missed forecasts by -22.22%. The prior quarter beat by -45.45%. Over the last six quarters, Apple has recorded several small beats. These include -99.1% in August 09, 2024.

Entera Bio Ltd. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.21. This means the shares are trading above this model’s fair value.

Entera Bio Ltd. (NASDAQ:ENTX) closed at $1.52 USD, losing -$0.12 (-7.32%) from the previous close of $1.64. The stock is currently mid-range between its 52-week high and low $1.00 and $3.22. With a market capitalization of about $69.70 million, Entera Bio Ltd. is classified as a micro-cap and shows higher-than-market volatility (beta ~1.84). Key stats such as the average daily volume over the past year has been around 193.02 thousand shares, in line with its 52-week average. Headquartered in Jerusalem, None, Entera Bio Ltd. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Miranda J. Toledano, the company employs approximately 18 people and listed since June 28, 2018. Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs.

Entera Bio Ltd. trades at a P/E ratio of -6.64, slightly below the S&P 500 average, with a price-to-sales ratio of 562.12 and a price-to-book ratio of 4.7 trading at moderately above to book value. The P/FCF stands at -9.49, also above market averages.

Our AI price prediction model suggests that Entera Bio Ltd. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -9.87%, with price expected at $1.37 by February 25, 2026, within a range of $1.25 to $1.50 3-Month Outlook: Projected fall of -61.84%, reaching $0.58 by May 12, 2026, with a range of $0.47 to $0.65. 1-Year Outlook: Projected gain of 426.32%, with price at $8.00 by February 11, 2027, within a range of $0.00 to $12.18.

Entera Bio Ltd. (NASDAQ:ENTX) shares are down -19.07% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Entera Bio Ltd. trading at a premium to the broader market with a P/E of -6.64. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $10.15, suggesting 567.76% upside. Our AI forecast model points to short-term weakness (-9.87% over two weeks), a medium-term fall (-61.84% over three months), and a longer-term gain (426.32% over one year), with expected trading ranges indicating moderate volatility.